Serina Therapeutics released FY2024 9 Months Earnings on November 12, 2024, with actual revenue of 70,000 USD and EPS of -4.7417

Brief Summary

Serina Therapeutics reported a third-quarter 2024 EPS of -4.8717 USD and revenue of 56,000 USD.

Impact of The News

The financial performance of Serina Therapeutics for Q3 2024 reveals significant losses, with an EPS of -4.8717 USD and low revenue of 56,000 USD. This indicates a challenging financial position for the company, missing typical industry expectations as other companies such as AppLovin have shown significant growth with a net profit of 4.34 billion USD and a revenue of 12 billion USD . In contrast, Serina’s financials suggest difficulties in achieving profitability and sustaining operations at current revenue levels. Consequently, the company might need to consider strategic adjustments such as cost reduction, restructuring, or focusing on revenue-generating activities to improve its financial health. The substantial loss implies a need for capital infusion or potential financing activities to support ongoing operations and business development.